{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:12:13Z","timestamp":1788527533070,"version":"build-2803163510"},"reference-count":120,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.autrev.2026.104169","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:48:00Z","timestamp":1787849280000},"page":"104169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modern diagnosis and treatment of multiple sclerosis: advances, challenges, and future directions"],"prefix":"10.1016","volume":"25","author":[{"given":"Pakeeran","family":"Siriratnam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mineesh","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Buzzard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robb","family":"Wesselingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Seery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilija","family":"Jokubaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tissa","family":"Wijeratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Skibina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saif","family":"Huda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Van der Walt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mastura","family":"Monif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2026.104169_bb0005","article-title":"Multiple sclerosis: emerging epidemiological trends and redefining the clinical course","volume":"44","author":"Portaccio","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.autrev.2026.104169_bb0010","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2026.104169_bb0015","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11910-022-01217-3","article-title":"The history of diagnosis and treatment of MS: a brief overview","volume":"22","author":"Murray","year":"2022","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.autrev.2026.104169_bb0020","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"Montalban","year":"2025","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106756","article-title":"Diagnostic evolution in multiple sclerosis: a narrative review of the McDonald criteria from 2001 to 2024","volume":"104","author":"Agrawal","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2026.104169_bb0030","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0035","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ana.27270","article-title":"New horizons for multiple sclerosis therapy: 2025 and beyond","volume":"98","author":"Sabatino","year":"2025","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0040","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1136\/jnnp-2016-315238","article-title":"Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study","volume":"88","author":"Lunde","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2026.104169_bb0045","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1474-4422(25)00275-3","article-title":"The use of optical coherence tomography and visual evoked potentials in the 2024 McDonald diagnostic criteria for multiple sclerosis","volume":"24","author":"Saidha","year":"2025","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0050","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1212\/WNL.0000000000201465","article-title":"Differentiating multiple sclerosis from AQP4-neuromyelitis optica spectrum disorder and MOG-antibody disease with imaging","volume":"100","author":"Cortese","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104169_bb0055","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S1474-4422(25)00304-7","article-title":"2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis","volume":"24","author":"Barkhof","year":"2025","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0060","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1136\/jnnp-2019-320493","article-title":"Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up","volume":"90","author":"Petzold","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2026.104169_bb0065","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/WNO.0000000000000704","article-title":"Visual evoked potentials as a biomarker in multiple sclerosis and associated optic neuritis","volume":"38","author":"Leocani","year":"2018","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.autrev.2026.104169_bb0070","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1002\/acn3.52165","article-title":"Retinal optical coherence tomography measures in multiple sclerosis: a systematic review and meta-analysis","volume":"11","author":"El Ayoubi","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0075","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41582-025-01115-5","article-title":"Advancing multiple sclerosis management in older adults","volume":"21","author":"van der Walt","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0080","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00415-024-12801-7","article-title":"The value of magnetic resonance imaging of the optic nerve for the diagnosis of multiple sclerosis in patients with optic neuritis","volume":"272","author":"Pihl-Jensen","year":"2025","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0085","doi-asserted-by":"crossref","first-page":"e733","DOI":"10.1212\/WNL.0000000000009832","article-title":"Optical coherence tomography for detection of asymptomatic optic nerve lesions in clinically isolated syndrome","volume":"95","author":"Outteryck","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104169_bb0090","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1212\/WNL.0000000000207507","article-title":"Diagnostic performance of adding the optic nerve region assessed by optical coherence tomography to the diagnostic criteria for multiple sclerosis","volume":"101","author":"Bsteh","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104169_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13112590","article-title":"Evolving the diagnosis of multiple sclerosis: a new landscape in light of the 2024 McDonald criteria","volume":"13","author":"Samara","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.autrev.2026.104169_bb0100","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/ana.25877","article-title":"Paramagnetic rim lesions are specific to multiple sclerosis: an international multicenter 3T MRI study","volume":"88","author":"Maggi","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0105","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1093\/brain\/awae013","article-title":"Imaging chronic active lesions in multiple sclerosis: a consensus statement","volume":"147","author":"Bagnato","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2026.104169_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.crad.2025.106984","article-title":"Central vein sign and paramagnetic rim lesion abbreviated counting methods for diagnosis of multiple sclerosis: a systematic review and meta-analysis","volume":"88","author":"Toljan","year":"2025","journal-title":"Clin Radiol"},{"key":"10.1016\/j.autrev.2026.104169_bb0115","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000214410","article-title":"Investigating the frequency and outcome of central vein sign and paramagnetic rim lesions in children with MOGAD","volume":"106","author":"Nistri","year":"2026","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104169_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102409","article-title":"Investigation of the \u201ccentral vein sign\u201d in infratentorial multiple sclerosis lesions","volume":"45","author":"Weber","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2026.104169_bb0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mri.2022.07.013","article-title":"Central vein sign in patients with inflammatory lesion of the upper cervical spinal cord on susceptibility weighted imaging at 3 tesla. Preliminary results","volume":"93","author":"Jensen-Kondering","year":"2022","journal-title":"Magn Reson Imaging"},{"key":"10.1016\/j.autrev.2026.104169_bb0130","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/13524585221134217","article-title":"Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: a consensus statement","volume":"29","author":"Hegen","year":"2023","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2026.104169_bb0135","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-025-12907-6","article-title":"CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective","volume":"272","author":"Di Sabatino","year":"2025","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/13524585221134213","article-title":"Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: a systematic review and meta-analysis","volume":"29","author":"Hegen","year":"2023","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2026.104169_bb0145","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/ene.14121","article-title":"Cerebrospinal fluid kappa and lambda free light chains in oligoclonal band-negative patients with suspected multiple sclerosis","volume":"27","author":"Ferraro","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0150","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000775","article-title":"Diagnostic accuracy of intrathecal kappa free light chains compared with OCBs in MS","volume":"7","author":"Duell","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2026.104169_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103765","article-title":"Oligoclonal bands and kappa free light chains: competing parameters or complementary biomarkers?","volume":"24","author":"Konen","year":"2025","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104169_bb0160","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000892","article-title":"Free light chains kappa can differentiate between myelitis and noninflammatory myelopathy","volume":"7","author":"Susse","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2026.104169_bb0165","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0170","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/ana.27145","article-title":"Towards a unified set of diagnostic criteria for multiple sclerosis","volume":"97","author":"Brownlee","year":"2025","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0175","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104169_bb0180","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1177\/1352458518808189","article-title":"Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial","volume":"24","author":"Fox","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2026.104169_bb0185","series-title":"41st congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025)","article-title":"Ocrelizumab vs placebo in primary progressive MS: efficacy and safety results of the Phase IIIb ORATORIO-HAND study","author":"Giovannoni","year":"2025"},{"key":"10.1016\/j.autrev.2026.104169_bb0190","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s40120-023-00532-2","article-title":"Treatment patterns and unmet need for patients with progressive multiple sclerosis in the United States: survey results from 2016 to 2021","volume":"12","author":"Watson","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1016\/j.autrev.2026.104169_bb0195","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2026.104169_bb0200","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104169_bb0205","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jamaneurol.2025.5068","article-title":"Beyond the single-disease paradigm-why distinctions in multiple sclerosis still matter","volume":"83","author":"Shirani","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0210","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1212\/WNL.0000000000003152","article-title":"The contemporary spectrum of multiple sclerosis misdiagnosis: a multicenter study","volume":"87","author":"Solomon","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104169_bb0215","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.msard.2019.01.048","article-title":"Incidence of multiple sclerosis misdiagnosis in referrals to two academic centers","volume":"30","author":"Kaisey","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2026.104169_bb0220","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/WCO.0000000000001362","article-title":"Red flags in multiple sclerosis","volume":"38","author":"Bulus","year":"2025","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0225","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/ana.25799","article-title":"Radiologically isolated syndrome: 10-year risk estimate of a clinical event","volume":"88","author":"Lebrun-Frenay","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0230","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2023.2815","article-title":"Teriflunomide and time to clinical multiple sclerosis in patients with radiologically isolated syndrome: the TERIS randomized clinical trial","volume":"80","author":"Lebrun-Frenay","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0235","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ana.26555","article-title":"Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome","volume":"93","author":"Okuda","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0240","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210274","article-title":"Investigating whether dissemination in time is essential to diagnose relapsing multiple sclerosis","volume":"104","author":"Brownlee","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104169_bb0245","article-title":"Relapse recovery in multiple sclerosis: effect of treatment and contribution to long-term disability","volume":"7","author":"Sotiropoulos","year":"2021","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.autrev.2026.104169_bb0250","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","article-title":"Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis","volume":"80","author":"Tur","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.70441","article-title":"Subclinical optic nerve involvement in radiologically isolated syndrome: multimodal detection and diagnostic impact","author":"Lebrun-Frenay","year":"2026","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0260","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104169_bb0265","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1007\/s00415-024-12294-4","article-title":"Radiologically isolated syndromes: to treat or not to treat?","volume":"271","author":"Preziosa","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0270","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104581","article-title":"Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: a systematic review and meta-analysis","volume":"71","author":"Pipek","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2026.104169_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2025.108117","article-title":"The TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) trial: design and baseline characteristics of participants","volume":"159","author":"Mowry","year":"2025","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.autrev.2026.104169_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106009","article-title":"Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: the DELIVER-MS study protocol","volume":"95","author":"Ontaneda","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.autrev.2026.104169_bb0290","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s43440-024-00642-0","article-title":"Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects","volume":"76","author":"Olejnik","year":"2024","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.autrev.2026.104169_bb0295","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208063","article-title":"Rituximab for multiple sclerosis: hiding in plain sight","volume":"102","author":"Langer-Gould","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104169_bb0300","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1474-4422(22)00426-4","article-title":"Family planning considerations in people with multiple sclerosis","volume":"22","author":"Krysko","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0305","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/jnnp-2025-338092","article-title":"Safety of breastfeeding under monoclonal antibodies in the offspring of mothers with multiple sclerosis or neuromyelitis optica spectrum disorder","volume":"97","author":"Witt","year":"2026","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2026.104169_bb0310","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2026.104169_bb0315","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0320","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209444","article-title":"Using the progression independent of relapse activity framework to unveil the pathobiological foundations of multiple sclerosis","volume":"103","author":"Ciccarelli","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104169_bb0325","doi-asserted-by":"crossref","first-page":"e1921","DOI":"10.1212\/WNL.0000000000008519","article-title":"Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data","volume":"93","author":"Goldman","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104169_bb0330","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1177\/13524585241256540","article-title":"Cognitive progression independent of relapse in multiple sclerosis","volume":"30","author":"Fuchs","year":"2024","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2026.104169_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2026.107080","article-title":"Cognition beyond relapses: cognitive progression independent of relapse activity reflects early smoldering neurodegeneration in multiple sclerosis","volume":"108","author":"Ziccardi","year":"2026","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2026.104169_bb0340","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1177\/13524585241264476","article-title":"The time to include cognition in the multiple sclerosis concept of progression independent from relapse activity is now","volume":"30","author":"Ziccardi","year":"2024","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2026.104169_bb0345","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s00415-025-13185-y","article-title":"Retinal neuronal loss and progression independent of relapse activity in multiple sclerosis","volume":"272","author":"Burguet Villena","year":"2025","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0350","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200092","article-title":"Visually evoked potential as prognostic biomarker for neuroaxonal damage in multiple sclerosis from a multicenter longitudinal cohort","volume":"10","author":"Oertel","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2026.104169_bb0355","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0360","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/jamaneurol.2023.0010","article-title":"Association of serum neurofilament light chain levels at disease onset with disability worsening in patients with a first demyelinating multiple sclerosis event not treated with high-efficacy drugs","volume":"80","author":"Monreal","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26104704","article-title":"Biomarkers of progression independent of relapse activity-can we actually measure it yet?","volume":"26","author":"Bsteh","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104169_bb0370","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaf306","article-title":"Persistent progression independent of relapse activity in multiple sclerosis","volume":"7","author":"Zhu","year":"2025","journal-title":"Brain Commun"},{"key":"10.1016\/j.autrev.2026.104169_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00601","article-title":"Progressive multiple sclerosis: evaluating current therapies and exploring future treatment strategies","volume":"22","author":"Albelo-Martinez","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.autrev.2026.104169_bb0380","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","article-title":"Bruton tyrosine kinase inhibitors for multiple sclerosis","volume":"19","author":"Kramer","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0385","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1474-4422(25)00174-7","article-title":"Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study","volume":"24","author":"Bar-Or","year":"2025","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0390","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1474-4422(24)00328-4","article-title":"Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials","volume":"23","author":"Montalban","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0395","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","article-title":"Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis","volume":"392","author":"Fox","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104169_bb0400","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa2415985","article-title":"Tolebrutinib versus teriflunomide in relapsing multiple sclerosis","volume":"392","author":"Oh","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104169_bb0405","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","article-title":"Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis","volume":"380","author":"Montalban","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104169_bb0410","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1177\/13524585241234783","article-title":"Efficacy and safety results after >3.5 years of treatment with the Bruton\u2019s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study","volume":"30","author":"Montalban","year":"2024","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2026.104169_bb0415","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","article-title":"Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Reich","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00602","article-title":"Beyond relapses: how BTK inhibitors are shaping the future of progressive MS treatment","volume":"22","author":"Naydovich","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.autrev.2026.104169_bb0425","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1352458517740641","article-title":"Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study","volume":"25","author":"Agius","year":"2019","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2026.104169_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103352","article-title":"Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum study","volume":"57","author":"Flanagan","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2026.104169_bb0435","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2309439","article-title":"Inhibition of CD40L with frexalimab in multiple sclerosis","volume":"390","author":"Vermersch","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104169_bb0440","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.autrev.2026.104169_bb0445","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1016\/j.cell.2025.09.020","article-title":"Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis","volume":"188","author":"Qin","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2026.104169_bb0450","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41582-024-01050-x","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT","volume":"21","author":"Muraro","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0455","series-title":"Global status report on neurology","author":"Organization WH","year":"2025"},{"key":"10.1016\/j.autrev.2026.104169_bb0460","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1212\/WNL.0000000000207739","article-title":"The Brain health imperative in the 21st century-a call to action: the AAN Brain health platform and position statement","volume":"101","author":"Rost","year":"2023","journal-title":"Neurology"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2026.104169_bb0465","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","article-title":"Brain health: time matters in multiple sclerosis","volume":"9","author":"Giovannoni","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2026.104169_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106456","article-title":"Brain health - time matters: multiple sclerosis, neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and related conditions. 2024 report","volume":"101","author":"Butzkueven","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2026.104169_bb0475","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.34675","article-title":"Premorbid sociodemographic status and multiple sclerosis outcomes in a universal health care context","volume":"6","author":"He","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.autrev.2026.104169_bb0480","doi-asserted-by":"crossref","first-page":"e2216","DOI":"10.1212\/WNL.0000000000008617","article-title":"Disability worsening among persons with multiple sclerosis and depression: a Swedish cohort study","volume":"93","author":"Binzer","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104169_bb0485","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1474-4422(17)30281-8","article-title":"Exercise in patients with multiple sclerosis","volume":"16","author":"Motl","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0490","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.msard.2024.105949","article-title":"Establishing consensus on lifestyle recommendations and behaviour change strategies to promote brain health-focussed care for multiple sclerosis: a modified e-Delphi study","volume":"92","author":"Wills","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2026.104169_bb0495","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000214688","article-title":"Performance of the 2024 McDonald criteria in patients under evaluation for suspected multiple sclerosis","volume":"106","author":"Brownlee","year":"2026","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104169_bb0500","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/13524585261421816","article-title":"Performance of the 2024 McDonald diagnostic criteria for multiple sclerosis","volume":"32","author":"Abad-Inchaurrondo","year":"2026","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2026.104169_bb0505","doi-asserted-by":"crossref","first-page":"106740","DOI":"10.1016\/j.msard.2025.106740","article-title":"Diagnostic yield of the revised 2024 McDonald\u2019s criteria for multiple sclerosis: insights from an Egyptian cohort","volume":"103","author":"Hamdy","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2026.104169_bb0510","doi-asserted-by":"crossref","first-page":"e624","DOI":"10.1212\/WNL.0000000000207481","article-title":"Global barriers to the diagnosis of multiple sclerosis: data from the Multiple Sclerosis International Federation atlas of MS, third edition","volume":"101","author":"Solomon","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104169_bb0515","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S1474-4422(23)00148-5","article-title":"Differential diagnosis of suspected multiple sclerosis: an updated consensus approach","volume":"22","author":"Solomon","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0520","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213907","article-title":"Sex-related gap in the use of disease-modifying therapies in multiple sclerosis","volume":"105","author":"Gavoille","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104169_bb0525","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1355817","article-title":"Priority setting: women\u2019s health topics in multiple sclerosis","volume":"15","author":"Ross","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0530","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/jamaneurol.2025.3538","article-title":"Menopause impact on multiple sclerosis disability progression","volume":"82","author":"Bridge","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0535","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251401510","article-title":"Shaping the role of plasma exchange in autoimmune neurology: lessons learned from 67 years and over 90,000 procedures","volume":"18","author":"Khatri","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.autrev.2026.104169_bb0540","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","article-title":"Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial","volume":"22","author":"Corboy","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0545","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/ene.14705","article-title":"Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: the VIAADISC score","volume":"28","author":"Bsteh","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106691","article-title":"Risk stratification for disease reactivation after therapy de-escalation\/discontinuation in relapsing multiple sclerosis by the VIAADISC score","volume":"103","author":"Bsteh","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2026.104169_bb0555","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jamaneurol.2024.4164","article-title":"Discontinuation of first-line disease-modifying therapy in patients with stable multiple sclerosis: the DOT-MS randomized clinical trial","volume":"82","author":"Coerver","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0560","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamaneurol.2024.0395","article-title":"High-efficacy therapy discontinuation vs continuation in patients 50 years and older with nonactive MS","volume":"81","author":"Jouvenot","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106625","article-title":"Exit strategies in patients with stable MS: cost-effectiveness of extended interval dosing of ocrelizumab and natalizumab versus de-escalating to cladribine","volume":"102","author":"Versteegh","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2026.104169_bb0570","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1474-4422(25)00249-2","article-title":"Blood and CSF biomarkers for multiple sclerosis: emerging clinical applications","volume":"24","author":"Chitnis","year":"2025","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0575","article-title":"Neurodegenerative biomarkers in multiple sclerosis: at the interface between research and clinical practice","volume":"15","author":"Ciubotaru","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.autrev.2026.104169_bb0580","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41746-024-01162-0","article-title":"A scoping review assessing the usability of digital health technologies targeting people with multiple sclerosis","volume":"7","author":"Tea","year":"2024","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.autrev.2026.104169_bb0585","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41746-024-01025-8","article-title":"Modeling multiple sclerosis using mobile and wearable sensor data","volume":"7","author":"Gashi","year":"2024","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.autrev.2026.104169_bb0590","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1407257","article-title":"The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care - updates at the 2023 plenary event","volume":"15","author":"Zaratin","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2026.104169_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106337","article-title":"Infectious mononucleosis is a more realistic target for preventing multiple sclerosis","volume":"95","author":"Giovannoni","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2026.104169_bb0600","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.840158","article-title":"Smoking attributable risk in multiple sclerosis","volume":"13","author":"Manouchehrinia","year":"2022","journal-title":"Front Immunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:12:51Z","timestamp":1788523971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":120,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1568997226001837"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104169","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modern diagnosis and treatment of multiple sclerosis: advances, challenges, and future directions","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104169","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104169"}}